Harvard Bioscience (HBIO) Operating Leases (2019 - 2026)

Harvard Bioscience (HBIO) has reported Operating Leases for 8 consecutive years, with $7.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 14.67% year-over-year to $7.5 million in Q2 2026; TTM through Jun 2026 was $7.5 million, a 14.67% decrease from a year earlier, with the FY2025 full-year figure at $8.4 million, up 11.51% from the prior year.
• Operating Leases was $7.5 million for Q2 2026 at Harvard Bioscience, down from $7.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $8.8 million in Q2 2025 and troughed at $5.8 million in Q1 2024.
• A 5-year average of $7.5 million and a median of $7.6 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases fell 18.59% in 2024 and soared 52.8% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $7.4 million in 2022, then fell by 16.27% to $6.2 million in 2023, then rose by 21.4% to $7.5 million in 2024, then gained by 11.51% to $8.4 million in 2025, then slipped by 10.5% to $7.5 million in 2026.
• The last three Operating Leases figures came in at $7.5 million (Q2 2026), $7.9 million (Q1 2026), and $8.4 million (Q4 2025), per Business Quant data.